Areas of Controversy in the Treatment Landscape of mCRC

September 12, 2018
Michael A. Choti, MD

Michael A. Choti, MD, chief of surgery at MD Anderson Cancer Center, discusses some controversial topics he sees in the treatment landscape of metastatic colorectal cancer.

Michael A. Choti, MD, chief of surgery at MD Anderson Cancer Center, discusses some controversial topics he sees in the treatment landscape of metastatic colorectal cancer (mCRC).

When metastases in patients with mCRC can potentially be resected, Choti says patients may still be offered a curative intent therapy over a surgical resection of the primary tumor. When there is a limited number of lung metastases or liver metastases in a patient, surgical therapy to resect those sites of disease should be offered.